Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer

Inclusion Criteria: * Age 18-75 years; able to provide written informed consent. * Histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma that is recurrent or refractory after standard therapy (at least 2 prior systemic regimens), with measurable disease per RECIST v1.1 and ECOG performance status 0-1. * Tumor tissue available for antigen assessment. Participant must meet protocol-defined positivity for the selected dual-target pair (example: 1 target expressed in \>=50% of tumor cells by IHC and the second target in \>=20%). * Adequate organ function per protocol-specified labs; negative pregnancy test nd agrees to use effective contraception for a protocol-defined period after infusion. Exclusion Criteria: * Active CNS metastases or carcinomatous meningitis (unless treated and stable for a protocol-defined period). * Prior gene-modified cell therapy targeting any of the study antigens (GD2, MUC1, PSMA, mesothelin) within 6 months. * Uncontrolled active infection (including uncontrolled HIV, HBV, or HCV) or active systemic fungal infection. * Clinically significant cardiovascular disease (e.g., recent myocardial infarction, unstable angina, uncontrolled arrhythmia) or LVEF \<50% . * Active autoimmune disease requiring systemic immunosuppression within 14 days prior to lymphodepletion (physiologic steroid replacement permitted). * History of organ transplantation or allogeneic hematopoietic stem cell transplantation. * Pregnant or breastfeeding. * Any condition that, in the investigator's judgment, would compromise participant safety or compliance.